01 9Concerta
02 1Concerta/ Methylphenidate
03 1Ritalin
04 1Ritalin/Focalin
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 622
2019 Revenue in Millions : 696
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 667
2020 Revenue in Millions : 622
Growth (%) : 7
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 644
2021 Revenue in Millions : 667
Growth (%) : -3
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 783
2022 Revenue in Millions : 644
Growth (%) : 22
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -23.40%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 599
2014 Revenue in Millions : 821
Growth (%) : 37%
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -17.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 492
2014 Revenue in Millions : 365
Growth (%) : -26%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 863
2015 Revenue in Millions : 821
Growth (%) : 5
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 791
2016 Revenue in Millions : 863
Growth (%) : -8
LOOKING FOR A SUPPLIER?
